S&P 500 Futures
(0.17%) 5 140.00 points
Dow Jones Futures
(0.11%) 38 484 points
Nasdaq Futures
(0.24%) 17 889 points
Oil
(-0.05%) $83.81
Gas
(0.78%) $1.938
Gold
(0.25%) $2 353.10
Silver
(0.62%) $27.71
Platinum
(2.20%) $942.35
USD/EUR
(-0.23%) $0.933
USD/NOK
(-0.41%) $10.98
USD/GBP
(-0.33%) $0.798
USD/RUB
(1.25%) $93.03

Echtzeitaktualisierungen für Botanix Pharmaceuticals [BOT.AX]

Börse: ASX Industrie: Pharmaceuticals, Biotechnology & Life Sciences
Zuletzt aktualisiert29 Apr 2024 @ 08:10

4.76% $ 0.220

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 08:10):

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections...

Stats
Tagesvolumen 3.27M
Durchschnittsvolumen 2.56M
Marktkapitalisierung 346.53M
EPS $0 ( 2024-02-25 )
Nächstes Ertragsdatum ( $0 ) 2024-07-28
Last Dividend $95.85 ( 1996-10-03 )
Next Dividend $0 ( N/A )
P/E -22.00
ATR14 $0.00200 (0.93%)

Volumen Korrelation

Lang: 0.12 (neutral)
Kurz: 0.22 (neutral)
Signal:(40.465) Neutral

Botanix Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Botanix Pharmaceuticals Korrelation - Währung/Rohstoff

The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.44
( neutral )

Botanix Pharmaceuticals Finanzdaten

Annual 2023
Umsatz: $914 973
Bruttogewinn: $-3.05M (-332.90 %)
EPS: $-0.00790
FY 2023
Umsatz: $914 973
Bruttogewinn: $-3.05M (-332.90 %)
EPS: $-0.00790
FY 2022
Umsatz: $2.75M
Bruttogewinn: $2.61M (94.79 %)
EPS: $-0.0135
FY 2021
Umsatz: $0.00
Bruttogewinn: $0.00 (0.00 %)
EPS: $-0.00438

Financial Reports:

No articles found.

Botanix Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Botanix Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $81.28 1994-02-18
Last Dividend $95.85 1996-10-03
Next Dividend $0 N/A
Payout Date 1996-10-25
Next Payout Date N/A
# dividends 6 --
Total Paid Out $510.23 --
Avg. Dividend % Per Year 0.00% --
Score 1.06 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-11-04)
$0 Estimate 0.00 %
Dividend Stability
0.01 Very Bad
Dividend Score
1.06
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
VEA.AX Ex Dividend Junior 2023-09-05 Semi-Annually 0 0.00%
DTL.AX Ex Dividend Knight 2023-09-14 Semi-Annually 0 0.00%
OPH.AX No Dividend Player 2023-06-30 Annually 0 0.00%
AGL.AX Ex Dividend Knight 2023-08-23 Semi-Annually 0 0.00%
GEM.AX Ex Dividend Junior 2023-09-07 Annually 0 0.00%
QRI.AX Ex Dividend Junior 2023-09-05 Monthly 0 0.00%
BFG.AX Ex Dividend Junior 2023-08-30 Semi-Annually 0 0.00%
JLG.AX Ex Dividend Junior 2023-09-01 Annually 0 0.00%
SKC.AX Ex Dividend Junior 2023-09-07 Annually 0 0.00%
CKF.AX Ex Dividend Knight 2023-07-10 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-11.081.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.2101.200-7.01-8.41[0 - 0.3]
returnOnEquityTTM-0.2931.500-4.37-6.56[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM9.500.80010.008.00[1 - 3]
quickRatioTTM8.090.80010.008.00[0.8 - 2.5]
cashRatioTTM7.991.50010.0010.00[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM-858.831.000-10.00-10.00[3 - 30]
operatingCashFlowPerShareTTM-0.007022.00-0.00234-0.00468[0 - 30]
freeCashFlowPerShareTTM-0.01862.00-0.00932-0.0186[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM-5.761.000-10.00-10.00[0.2 - 0.8]
operatingProfitMarginTTM-11.101.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.01900.800-3.21-2.57[0.5 - 2]
Total Score-3.67

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-31.581.000-3.290[1 - 100]
returnOnEquityTTM-0.2932.50-2.81-6.56[0.1 - 1.5]
freeCashFlowPerShareTTM-0.01862.00-0.00621-0.0186[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.007022.00-0.00234-0.00468[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.1061.500-2.620[0.5 - 2]
operatingCashFlowSalesRatioTTM-11.171.000-10.000[0.1 - 0.5]
Total Score-2.43

Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.

Über Live-Signale

Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.

Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.